Understanding how Nras mutations affect treatment responses in a type of leukemia.
Official title: Characterizing Oncogenic Nras in IDH1 Mutant AML Leukemogenesis and Therapeutic Responsiveness
Funded at Weill Medical Coll of Cornell Univ · NIH-10902958 · Data updated 2026-11-12
This study is looking at how certain changes in a gene called Nras affect people with Acute Myeloid Leukemia who also have changes in another gene called IDH, with the goal of finding better treatments for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $53,974 |
| NIH project number | 1F30CA284575-01A1 |
| Project ID | NIH-10902958 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with Acute Myeloid Leukemia who have Isocitrate Dehydrogenase mutations and may also have Nras mutations.
✕Less likely to help
Patients without IDH mutations or those with other types of leukemia may not benefit from this research.
What this research studies
This research investigates the role of oncogenic Nras mutations in Acute Myeloid Leukemia (AML) that has Isocitrate Dehydrogenase (IDH) mutations. By using advanced mouse models that mimic human disease, the study aims to uncover how Nras mutations contribute to the development of leukemia and resistance to current therapies. The research will explore the mechanisms behind these mutations and their impact on treatment outcomes, potentially leading to improved therapeutic strategies for patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with IDH mutant AML, particularly those with Nras mutations.
How similar studies have gone: While the specific approach of studying Nras in the context of IDH mutant AML is novel, previous research has shown that targeting genetic mutations can lead to breakthroughs in cancer treatment.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Gelfer, Rebecca — Weill Medical Coll of Cornell Univ
- Study coordinator: Gelfer, Rebecca
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.